\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ follow\\-up\\ apparent\\.\\ hematuria\\ symptoms\\ resolved\\.\ \(0\)\
\-\ abnormal\\ study\\ with\\ development\\ of\\ thin\\ cortical\\ calcifications\\,\\ which\\ extend\\ into\\ the\\ medullary\\ spaces\\ along\\ the\\ columns\\ of\\ bertin\\,\\ as\\ well\\ as\\ heterogeneous\\ enhancement\\ of\\ the\\ kidneys\\ and\\ minimal\\ delayed\\ excretion\\.\ \(0\)\
\-\ the\\ overall\\ pattern\\ is\\ compatible\\ with\\ acute\\ cortical\\ necrosis\\.\ \(0\)\
\-\ cortical\\ nephrocalcinosis\\ due\\ to\\ acute\\ renal\\ cortical\\ necrosis\ \(0\)\
\-\ acute\\ renal\\ cortical\\ necrosis\ \(2\)\
\-\ primary\\/secondary\\ oxalosis\ \(0\)\
\-\ chronic\\ glomerulonephritis\ \(1\)\
\-\ alports\\ syndrome\\ \\(glomerulonephritis\\,\\ endstage\\ kidney\\ disease\\,\\ and\\ hearing\\ loss\\)\\ \ \(0\)\
\-\ intrarenal\\ infection\\ in\\ hiv\\+\ \(0\)\
\-\ amphotericin\\ b\ \(0\)\
\-\ acute\\/chronic\\ renal\\ allograft\\ rejection\ \(0\)\
\-\ autosomal\\ recessive\\ polycystic\\ disease\ \(0\)\
\-\ 50\\ yo\\ woman\\ with\\ history\\ of\\ retroperitoneal\\ paraganglioma\\,\\ s\\/p\\ resection\\.\\ patient\\ developed\\ gross\\ hematuria\\ one\\ week\\ post\\-op\\.\\ ct\\ for\\ hematuria\\ revealed\\ an\\ incidental\\ finding\\.\ \(0\)\
\-\ patient\\ had\\ episode\\ of\\ hypotension\\ during\\ paraganglioma\\ resection\\.\\ hypotension\\ hypothesized\\ to\\ have\\ induced\\ acute\\ renal\\ cortical\\ necrosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cortical\\:\\ 0\\.13162288101024558\ \(0\)\
\-\ necrosis\\:\\ 0\\.09501692150548464\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.0891635461151901\ \(0\)\
\-\ hematuria\\:\\ 0\\.08563403850356498\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.07449518168099066\ \(0\)\
\-\ hypotension\\:\\ 0\\.07369013359873787\ \(0\)\
\-\ renal\\:\\ 0\\.07232325491431181\ \(0\)\
\-\ primary\\/secondary\\:\\ 0\\.06208111566173591\ \(0\)\
\-\ alports\\:\\ 0\\.06208111566173591\ \(0\)\
\-\ acute\\:\\ 0\\.05943322053821114\ \(0\)\
\-\ oxalosis\\:\\ 0\\.05719979748877854\ \(0\)\
\-\ acute\\/chronic\\:\\ 0\\.05719979748877854\ \(0\)\
\-\ endstage\\:\\ 0\\.05434440940350978\ \(0\)\
\-\ hiv\\+\\:\\ 0\\.05231847931582118\ \(0\)\
\-\ rejection\\:\\ 0\\.050747045855861955\ \(0\)\
\-\ hypothesized\\:\\ 0\\.050747045855861955\ \(0\)\
\-\ columns\\:\\ 0\\.04837752306275482\ \(0\)\
\-\ bertin\\:\\ 0\\.04837752306275482\ \(0\)\
\-\ allograft\\:\\ 0\\.04837752306275482\ \(0\)\
\-\ intrarenal\\:\\ 0\\.045865727682904596\ \(0\)\
\-\ amphotericin\\:\\ 0\\.04458177305759505\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.04212890901345269\ \(0\)\
\-\ recessive\\:\\ 0\\.04000017047913626\ \(0\)\
\-\ excretion\\:\\ 0\\.03887099688705753\ \(0\)\
\-\ resection\\:\\ 0\\.03753402331718618\ \(0\)\
\-\ induced\\:\\ 0\\.03610309133698987\ \(0\)\
\-\ polycystic\\:\\ 0\\.035593790903330536\ \(0\)\
\-\ post\\-op\\:\\ 0\\.03527363333940971\ \(0\)\
\-\ autosomal\\:\\ 0\\.03481913671168033\ \(0\)\
\-\ compatible\\:\\ 0\\.03324770325172111\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.03206224328820551\ \(0\)\
\-\ extend\\:\\ 0\\.030161400921220015\ \(0\)\
\-\ overall\\:\\ 0\\.029937818538722974\ \(0\)\
\-\ episode\\:\\ 0\\.02979261229081638\ \(0\)\
\-\ spaces\\:\\ 0\\.029650339704073287\ \(0\)\
\-\ hearing\\:\\ 0\\.029650339704073287\ \(0\)\
\-\ resolved\\:\\ 0\\.029173870348623884\ \(0\)\
\-\ medullary\\:\\ 0\\.0289154100186913\ \(0\)\
\-\ gross\\:\\ 0\\.02866610067326231\ \(0\)\
\-\ b\\:\\ 0\\.02836638507876375\ \(0\)\
\-\ kidneys\\:\\ 0\\.027695186629437516\ \(0\)\
\-\ apparent\\:\\ 0\\.026609618461639926\ \(0\)\
\-\ development\\:\\ 0\\.02620963537436434\ \(0\)\
\-\ s\\/p\\:\\ 0\\.02524232258529515\ \(0\)\
\-\ thin\\:\\ 0\\.024733897999348047\ \(0\)\
\-\ delayed\\:\\ 0\\.024492819325811127\ \(0\)\
\-\ minimal\\:\\ 0\\.02369352091831548\ \(0\)\
\-\ developed\\:\\ 0\\.023169475245314892\ \(0\)\
\-\ pattern\\:\\ 0\\.02300311506388224\ \(0\)\
\-\ 50\\:\\ 0\\.022894352229885947\ \(0\)\
\-\ incidental\\:\\ 0\\.022787243647748423\ \(0\)\
\-\ calcifications\\:\\ 0\\.02237439263825882\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.02212813490700708\ \(0\)\
\-\ kidney\\:\\ 0\\.021199883486267675\ \(0\)\
\-\ week\\:\\ 0\\.020436728298086113\ \(0\)\
\-\ along\\:\\ 0\\.019887703358158565\ \(0\)\
\-\ study\\:\\ 0\\.01980022082295746\ \(0\)\
\-\ disease\\:\\ 0\\.019672359735432455\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.019577725291843255\ \(0\)\
\-\ finding\\:\\ 0\\.01939479933125691\ \(0\)\
\-\ revealed\\:\\ 0\\.0193131964075077\ \(0\)\
\-\ during\\:\\ 0\\.018415558098054986\ \(0\)\
\-\ as\\:\\ 0\\.018205316984424336\ \(0\)\
\-\ yo\\:\\ 0\\.018108109319033536\ \(0\)\
\-\ infection\\:\\ 0\\.017493074465301458\ \(0\)\
\-\ loss\\:\\ 0\\.017468057552594646\ \(0\)\
\-\ syndrome\\:\\ 0\\.017210609695314377\ \(0\)\
\-\ abnormal\\:\\ 0\\.01716262141066839\ \(0\)\
\-\ chronic\\:\\ 0\\.01695063121765493\ \(0\)\
\-\ one\\:\\ 0\\.016307967488103127\ \(0\)\
\-\ enhancement\\:\\ 0\\.01613020257833124\ \(0\)\
\-\ due\\:\\ 0\\.01605828980952704\ \(0\)\
\-\ symptoms\\:\\ 0\\.014997587865479852\ \(0\)\
\-\ into\\:\\ 0\\.014319199774364133\ \(0\)\
\-\ woman\\:\\ 0\\.013900724982316242\ \(0\)\
\-\ well\\:\\ 0\\.013613246147666557\ \(0\)\
\-\ have\\:\\ 0\\.013031254072993605\ \(0\)\
\-\ had\\:\\ 0\\.012984857881976819\ \(0\)\
\-\ patient\\:\\ 0\\.012064675083329408\ \(0\)\
\-\ which\\:\\ 0\\.011233412586215132\ \(0\)\
\-\ \\,\\:\\ 0\\.009532044560467866\ \(0\)\
\-\ ct\\:\\ 0\\.008417631361915796\ \(0\)\
\-\ an\\:\\ 0\\.008321583551300915\ \(0\)\
\-\ history\\:\\ 0\\.0083113699838527\ \(0\)\
\-\ no\\:\\ 0\\.006059465850026775\ \(0\)\
\-\ to\\:\\ 0\\.00601504378088713\ \(0\)\
\-\ for\\:\\ 0\\.005134564427061374\ \(0\)\
\-\ \\(\\:\\ 0\\.005087054410168032\ \(0\)\
\-\ \\)\\:\\ 0\\.005024913324741585\ \(0\)\
\-\ of\\:\\ 0\\.0041022465069714235\ \(0\)\
\-\ is\\:\\ 0\\.003959794213976941\ \(0\)\
\-\ the\\:\\ 0\\.003894346047989459\ \(0\)\
\-\ in\\:\\ 0\\.002967586127748274\ \(0\)\
\-\ and\\:\\ 0\\.002535338108904485\ \(0\)\
\-\ with\\:\\ 0\\.0024719192131666843\ \(0\)\
\-\ \\.\\:\\ 0\\.0022499705977191303\ \(0\)\
